February 27, 2007

Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The CD40 agonist mAb CP-870,893 was well tolerated and biologically active, and was associated with antitumor activity. Further studies of repeated doses of CP-870,893 alone and in combination with other antineoplastic agents are warranted.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Vonderheide et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d9260d8988aeabbe68453c — DOI: https://doi.org/10.1200/jco.2006.08.3311

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients· 2001 · 225 citations
Molecular and biological characterization of a murine ligand for CD40· 1992 · 1,024 citations
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell· 1998 · 2,338 citations
The role of the CD40 pathway in the pathogenesis and treatment of cancer· 2004 · 99 citations
CD40-CD40 ligand

Authors

Robert H. Vonderheide

Keith T. Flaherty

Magi Khalil

Journals

Journal of Clinical Oncology

Actions

Institutions

University of Pennsylvania

Pfizer (United States)

Moffitt Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion